Court Rules In Pfizer's Favor In Norvasc Patent Case

Law360, New York (January 31, 2007, 12:00 AM EST) -- In yet another setback for Dutch drug maker Synthon Pharmaceuticals Inc., a U.S. judge has agreed with defendant Pfizer Inc. that Synthon’s patent for generic Norvasc was gleaned through inequitable conduct.

According to a sealed order issued Jan. 29, Synthon intentionally withheld from the U.S. Patent and Trademark Office certain publications by Pfizer and other information that described the process Synthon was patenting.

Due to Synthon’s alleged behavior during patent prosecution, the patent-in-suit was deemed unenforceable and not infringed by Judge T. S. Ellis III in...
To view the full article, register now.